Clinical trials: Refractory Neoplasm
Acute Lymphoblastic Leukemia, B-cell Lymphoma
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in treating patients with relapsed/refractory/high-risk B-cell tumors.
- Conditions
- Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT04814004
- Testing
- hCD19.IL15.CAR-iNKT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Kai Lin Xu; Jun Nian Zheng
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Some tumors are difficult to treat with chemotherapy or radiation. One of the reasons is that areas of the tumor do not have many blood vessels, which makes it difficult for drugs to reach those areas.
- Conditions
- Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs
- Trial name
- NCT03435952
- Testing
- Pembrolizumab, Clostridium Novyi-NT, Doxycycline
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma
- Trial name
- NCT01082926
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
Solid Tumors
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors
The purpose of this research study is to find out what side effects the combination of the two study drugs, bevacizumab (Avastin) and CNTO 95 have on the body and to determine the highest dose of CNTO 95 that can be given with…
- Trial name
- CNTO95/Avastin (NCT00888043)
- Testing
- CNTO 95 and avastin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Herbert Hurwitz, MD
Breast Cancer
A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
For locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not…
- Trial name
- NCT07672743
- Testing
- Radical dose radiotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumor
Study of CMTS1215 Injection in Patients With Solid Tumors
This is a prospective, open-label, single-arm exploratory clinical trial to evaluate the safety and efficacy of CMTS1215 (Proteus mirabilis) oncolytic bacteria injection for the treatment of solid tumors.
- Trial name
- NCT07556276
- Testing
- CMTS1215 Oncolytic Bacteria
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Lymphoma, Non-Hodgkin
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy.
- Trial name
- NCT05824585
- Testing
- DZD8586
- Where
- 5 sites in United States, Australia
- Volunteers
- 17 people
- Sponsor
- Dizal Pharmaceuticals
Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
This phase I trial tests the safety, side effects, and best dose of FL118 in treating patients with pancreatic ductal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts…
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06206876
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Gastric Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.
- Trial name
- NCT00681252
- Testing
- URLC10, VEGFR1 and VEGFR2
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
Diffuse Large B Cell Lymphoma
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19 CAR NK cells in patients with B-cell Non Hodgkin Lymphoma.
- Trial name
- NCT05673447
- Testing
- anti-CD19 CAR NK cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Changhai Hospital
Gastrointestinal Cancer
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow.
- Trial name
- NCT01058655
- Testing
- Everolimus, Tivozanib
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerated dose of rAd.CD40L (also called ISF35) when given with pembrolizumab to patients with melanoma.
- Trial name
- NCT02719015
- Testing
- rAd.CD40L, Pembrolizumab
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
This is a single center, prospective cohort study to to evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation(ASCT) bridging chimeric antigen receptor T (CART) cell therapy in the treatment of…
- Trial name
- NCT04923789
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Unspecified Childhood Solid Tumor, Protocol Specific
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
RATIONALE: AT9283 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in children and adolescents with…
- Trial name
- NCT00985868
- Testing
- multikinase inhibitor AT9283, enzyme-linked immunosorbent assay, immunohistochemistry staining method
- Where
- 5 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- Cancer Research UK
CD19 Positive, CD22 Positive
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia…
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease
- Trial name
- NCT04029038
- Testing
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Reccurent/Metastatic Solid Tumor Disease
A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer.
- Trial name
- SHIVA (NCT01771458)
- Testing
- Targeted therapy based on molecular profiling : Imatinib, Tumor biopsy, Standard Chemotherapy
- Where
- 8 sites in France
- Volunteers
- 742 people
- Sponsor
- Institut Curie
Central Nervous System Neoplasms, Pediatric Cancer
Pediatric Prospective Personalized Immune and Target Identification Trial
PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.
- Conditions
- Central Nervous System Neoplasms, Pediatric Cancer, GEN1 Gene Mutation, Tumor, Brain
- Trial name
- PPROSPERITIT (NCT04859543)
- Testing
- FoundationOneHeme
- Where
- 3 sites in Austria, Czechia
- Volunteers
- 80 people
- Sponsor
- Masaryk University
Lymphoid Malignancies, Lymphoma
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
This is an open label, phase I/IIa, 3 x 3 dose escalation study with an initial phase I followed by a disease focused phase II. The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and dose…
- Conditions
- Lymphoid Malignancies, Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Trial name
- NCT01998035
- Testing
- RomiDEPsin 10 MG/M2, Oral 5-Azacitidine 100 MG, Romidepsin 14 MG/M2
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Columbia University
Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
This is a Phase II/III, open-label, single-arm, multicenter study of intravesical BCG plus N-803 or N-803 only in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT03022825
- Testing
- N-803 and BCG, N-803
- Where
- 28 sites in United States
- Volunteers
- 190 people
- Sponsor
- ImmunityBio, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.